GET DAILY SIGNALSImmix Biopharma (IMMX) Q3 2026 Earnings: Clinical Data Takes Center Stage
Key Takeaways
- Immix Biopharma is set to release third-quarter 2026 results around November 6, 2026, followed by a conference call on November 10, 2026.
- Wall Street consensus anticipates a net loss of about $0.18 per share and revenue close to zero, reflecting the company’s clinical-stage position.
- Attention will likely center on cash runway, operating expense patterns, and any fresh details on the lead CAR-T candidate NXC-201.
- Positive interim data released in late September 2026 showed an 89% complete response rate in the NEXICART-2 trial for relapsed/refractory AL Amyloidosis.
- Recent quarters have shown a mixed record versus estimates, with a modest miss last quarter tied to higher spending.
- For additional background on Immix Biopharma, readers may review the Major News, Today’s Price Move, Price Targets, and Forecast sections.
- Those seeking broader market ideas can also look at Trending AI Robots for other trade concepts and signals.
Why This Earnings Report Matters
Immix Biopharma develops cell therapies for blood cancers and related conditions, with its BCMA-targeted CAR-T therapy NXC-201 aimed at relapsed/refractory AL Amyloidosis. As a pre-commercial company, the quarterly update offers little in the way of revenue but serves as an important check on spending discipline and available cash. The September 2026 interim results, which delivered an 89% complete response rate in the NEXICART-2 trial, have heightened interest in the program’s route to a Biologics License Application. I’m watching closely to see whether management confirms development timelines and confirms sufficient funding through a potential launch.
What Analysts Expect
Consensus calls for a net loss near $0.18 per share and essentially no revenue, in line with other clinical-stage biotechs. In the June 2026 quarter, the company posted a loss of $0.18 per share against a $0.17 estimate after general and administrative costs rose sharply year over year. The first quarter of 2026 showed a loss of $0.18 per share, beating the $0.21 consensus. A $140.7 million public offering completed in May 2026 bolstered the balance sheet, leaving reported cash of roughly $232.1 million to support Phase 3 work and BLA preparations. Beyond the headline loss figure, I expect investors to focus on research and development outlays, administrative costs, and any comments on cash runway extending into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Investor focus ahead of the report has been driven more by clinical updates than by financials. Shares of Immix Biopharma have tended to move on NXC-201 readouts and financing news, with the May 2026 data release accompanied by a drop after the company announced a $150 million offering. The late September update highlighted strong response rates and no observed neurotoxicity, underscoring clinical progress while also highlighting execution risks around a BLA filing and eventual commercialization. For the earnings release itself, the market will probably emphasize expense control, cash runway clarity, and any forward comments on trial schedules rather than the bottom-line number alone.
Key Items to Watch Going Forward
After the report, management commentary on the timing of the NEXICART-2 topline readout and BLA submission will be important. The company has guided for final readout and BLA filing in 2027, with one-year follow-up data expected by the end of March 2027. Any shift in that schedule would carry meaningful implications for the investment case. Cash runway is another central point. With roughly $232.1 million on hand after the May offering, investors will seek clarity on how long those reserves are projected to last and whether further financing could be needed before commercialization. Rising general and administrative expenses have also drawn attention in recent periods. Finally, competitive dynamics in AL Amyloidosis, including bispecific approaches from larger pharmaceutical firms, remain relevant. NXC-201’s durability, safety profile, and one-time treatment format form the core of the company’s differentiation narrative. Clinical updates, regulatory milestones, and spending discipline will be the main factors to track in coming quarters.
Using Tickeron’s AI Screener for Biotech Research
I often turn to Tickeron’s AI Screener when reviewing clinical-stage names like this one. The tool lets me quickly filter biotechnology stocks by fundamentals, volatility, and performance metrics, which helps place individual companies in broader context without spending hours on manual screening. It has become a regular part of my workflow for identifying comparable names and monitoring sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMMX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMMX turned positive on October 27, 2026. Looking at past instances where IMMX's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMMX's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMX advanced for three days, in 202 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
IMMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for IMMX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IMMX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.519) is normal, around the industry mean (2.788). P/E Ratio (-9.159) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. IMMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement